LivaNova (NASDAQ:LIVN) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report issued on Thursday.

According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “

LIVN has been the topic of several other reports. BidaskClub upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Saturday, March 24th. BTIG Research reiterated a “hold” rating on shares of LivaNova in a research report on Thursday, May 3rd. Canaccord Genuity lifted their target price on shares of LivaNova from $76.00 to $81.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. ValuEngine upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of LivaNova in a research report on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $81.43.

Shares of LivaNova opened at $83.23 on Thursday, MarketBeat Ratings reports. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.03. LivaNova has a twelve month low of $84.18 and a twelve month high of $84.64. The stock has a market cap of $4.11 billion, a PE ratio of 25.15, a price-to-earnings-growth ratio of 2.67 and a beta of 0.77.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 2nd. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. LivaNova had a negative net margin of 1.99% and a positive return on equity of 8.38%. The business had revenue of $250.40 million for the quarter, compared to analyst estimates of $245.18 million. During the same period in the previous year, the business earned $0.67 EPS. The firm’s revenue was up 10.4% on a year-over-year basis. research analysts forecast that LivaNova will post 3.18 earnings per share for the current year.

In other LivaNova news, Director Alfred J. Novak sold 1,000 shares of the business’s stock in a transaction dated Wednesday, May 9th. The shares were sold at an average price of $84.02, for a total value of $84,020.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David S. Wise sold 1,500 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $88.17, for a total transaction of $132,255.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,000 shares of company stock worth $521,040. Company insiders own 0.28% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. LS Investment Advisors LLC boosted its position in LivaNova by 41.3% in the fourth quarter. LS Investment Advisors LLC now owns 4,957 shares of the company’s stock valued at $396,000 after buying an additional 1,450 shares in the last quarter. Invictus RG boosted its position in LivaNova by 69.2% in the fourth quarter. Invictus RG now owns 9,302 shares of the company’s stock valued at $743,000 after buying an additional 3,805 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in LivaNova by 88.6% in the fourth quarter. Crossmark Global Holdings Inc. now owns 7,090 shares of the company’s stock valued at $567,000 after buying an additional 3,330 shares in the last quarter. Teacher Retirement System of Texas boosted its position in LivaNova by 321.0% in the fourth quarter. Teacher Retirement System of Texas now owns 14,239 shares of the company’s stock valued at $1,138,000 after buying an additional 10,857 shares in the last quarter. Finally, BlackRock Inc. boosted its position in LivaNova by 3.2% in the fourth quarter. BlackRock Inc. now owns 4,796,615 shares of the company’s stock valued at $383,345,000 after buying an additional 149,678 shares in the last quarter. Hedge funds and other institutional investors own 86.12% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Get a free copy of the Zacks research report on LivaNova (LIVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.